Home > Insider Trading > Filing (0001209191-11-023614)

Filing Details

Accession Number:: 0001209191-11-023614
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-04-20 12:53:03
Reporting Period:: 2011-04-18

Filing Date:: 2011-04-20
Accepted Time:: 2011-04-20 12:53:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1367644	Emergent Biosolutions Inc.	EBS	Pharmaceutical Preparations (2834)	141902018

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1380185	Fuad El-Hibri	2273 Research Boulevard, Suite 400 Rockville MD 20850	Ceo & Chairman	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2011-04-18	26,185	$23.20	1,146,773	No	4	S	Direct
Common Stock	Disposition	2011-04-19	2,226	$24.07	1,144,547	No	4	S	Direct
Common Stock	Disposition	2011-04-18	7,000	$23.31	6,136,794	No	4	S	Indirect	By Intervac, L.L.C.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	By Intervac, L.L.C.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,524,155	Indirect	By Biovac, L.L.C.
Common Stock	10,428	Indirect	By Karim El-Hibri Trust
Common Stock	10,428	Indirect	By Yusra El-Hibri Trust
Common Stock	10,428	Indirect	By Faiza El-Hibri Trust
Common Stock	2,265,043	Indirect	By BioPharm,L.L.C.

Footnotes

This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line, range from $23.00 to $24.00. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. El-Hibri on March 14, 2011. Mr. El-Hibri's direct holdings include restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.
This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $24.00 to $24.09. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $23.01 to $24.00. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Intervac, L.L.C. on March 15, 2011. Intervac, L.L.C. was the direct owner of the shares of Common Stock sold pursuant to the Rule 10b5-1 trading plan, and was or is the direct owner of the shares of Common Stock reported as beneficially owned immediately following the reported sales. Both before and after the reported sales, Mr. El-Hibri held, individually and with his wife, as tenants by the entirety, an aggregate 41.1072% equity interest in Intervac, L.L.C. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Intervac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest in 2,522,665 shares.
Mr. El-Hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,524,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Biovac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest in 1,359,546 shares.
These shares are held in a trust for the benefit of a child of the reporting person. The reporting person is trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 2,265,043 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 909,868 shares.